PEMBROLIZUMAB (KEYTRUDA®) – The treatment of advanced melanoma
(or advanced/ metastatic NSCLC EMAS patients only - nov 2016)

DRUG ADMINISTRATION SCHEDULE

<table>
<thead>
<tr>
<th>Day</th>
<th>Drug</th>
<th>Daily Dose</th>
<th>Route</th>
<th>Diluent</th>
<th>Rate</th>
</tr>
</thead>
<tbody>
<tr>
<td>Day 1</td>
<td>Pembrolizumab</td>
<td>2mg/kg*</td>
<td>IV Infusion</td>
<td>100mL* 0.9% Sodium Chloride Or 5% Glucose</td>
<td>Over 30 minutes</td>
</tr>
</tbody>
</table>

- Supplied as 50mg vials consider rounding the dose to the nearest 50mg to avoid waste or vial share.
- Final concentration must be between 1 to 10mg/mL

CYCLE LENGTH AND NUMBER OF DAYS
2 mg/kg administered intravenously over 30 minutes, every 21 days (3 weeks) until disease progression or unacceptable toxicity.

APPROVED INDICATIONS
Pembrolizumab as monotherapy is indicated for the treatment of advanced melanoma in adults either before or after ipilimumab. (NICE TA’s 357 and 366)

Currently under the Early Access to Medicines Scheme (EAMS), pembrolizumab as monotherapy is indicated treatment naïve NSCLC patients (1st line treatment for stage IV metastatic disease). Note: Pembrolizumab was previously available under EAMS scheme for NSCLC patients who had received at least one prior chemotherapy regimen.

NSCLC patients must have tumours that express PD-L1 as determined by a validated test, must not have received prior systemic therapy, must be negative for EGFR sensitising mutation and ALK translocation, or must have experienced disease progression on or after platinum-containing chemotherapy.

ELIGIBILITY CRITERIA
See indications.

EXCLUSION CRITERIA
None

CONTRAINDICATIONS
Hypersensitivity to the active substance or any of the excipients e.g. L-histidine, polysorbate 80. Patients with hepatitis B or hepatitis C infection; active systemic autoimmune disease; interstitial lung disease; prior pneumonitis requiring systemic corticosteroid therapy; a history of severe hypersensitivity to another monoclonal antibody
PREMEDICATION
None routinely recommended.
Consider premedication with antipyretic (paracetamol) and antihistamine (chlorphenamine) in patients with mild or moderate infusion reactions (close monitoring required.)

RECOMMENDED TAKE HOME MEDICATION
Not routinely required, however patients should be counselled to report side effects (e.g. severe diarrhoea) early to allow for prompt intervention.
Loperamide 2mg as required.

INVESTIGATIONS / MONITORING REQUIRED
- Pre-treatment: Assessment of renal function, FBC, Cardiac history, FBC, U&E’s, glucose, LFT’s and tumour markers as appropriate.
- Prior to each cycle: FBC, U&E’s, glucose, and LFT’s.

ASSESSMENT OF RESPONSE
Metastatic: Tumour size and patient symptomatic response. CT scans after x cycles, or in response to symptoms.

Atypical responses (i.e. an initial transient increase in tumour size or small new lesions within the first few months followed by tumour shrinkage) have been observed. SPC recommends continuing treatment for clinically stable patients with initial evidence of disease progression until disease progression is confirmed.

REVIEW BY CLINICIAN
To be reviewed either by a Nurse, Pharmacist or Clinician before every cycle.

NURSE / PHARMACIST LED REVIEW
Each cycle as applicable according to local protocols.

ADMINISTRATION NOTES

CAUTION
Pembrolizumab administration can result in severe and fatal immune-mediated adverse reactions (irAEs). irAEs may involve gastrointestinal, endocrine, skin, liver, nervous, lung and other organ systems. Unless an alternate aetiology has been identified, signs and symptoms suggestive of irAEs must be considered inflammatory and Immunotherapy related. Early diagnosis and appropriate management are essential to minimise life threatening complications.

Systemic high dose corticosteroid with or without additional immunosuppressive therapy may be required for management of severe irAEs

- Risk of infusion related reactions (see non-haematological toxicity section below.)
- Administer using a low-protein binding 0.2-5um in-line or add-on filter.
- Consider premedication with antipyretic and antihistamine in patients with mild or moderate infusion reactions (close monitoring required.)
• The use of systemic corticosteroids or immunosuppressants before starting pembrolizumab should be avoided because of their potential interference with the pharmacodynamic activity and efficacy of pembrolizumab. However, systemic corticosteroids or other immunosuppressants can be used after starting pembrolizumab to treat immune related adverse reactions.
• All patients must be provided with the Patient Alert Card with each prescription as per the marketing authorisation.

EXTRAVASATION  See NECN/Local Policy

TOXICITIES (None Immune related)
• Diarrhoea
• Fatigue
• Rash
• Pruritus
• Nausea & vomiting
• Arthralgia
• Anaemia
• Hyper/hypothyroidism

The majority of adverse reactions reported were of Grade 1 or 2 severity. The most serious adverse reactions were immune-related adverse reactions and severe infusion-related reactions (see non-haematological toxicity section below.)

DOSE MODIFICATION / TREATMENT DELAYS

Haematological Toxicity

<table>
<thead>
<tr>
<th>Neutrophils (x 10⁹/L)</th>
<th>Platelets (x 10⁹/L)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥ 1.0</td>
<td>≥ 50</td>
<td>100% dose</td>
</tr>
<tr>
<td>≤ 0.5</td>
<td>Or ≤ 25</td>
<td>Discuss with the Consultant. Dose delays are not recommended, consider discontinuation.</td>
</tr>
</tbody>
</table>

Non-Haematological Toxicity

Infusion Related Reactions
For severe infusion reactions, stop infusion and permanently discontinue pembrolizumab. However, patients with mild or moderate infusion reactions may continue to receive pembrolizumab with close monitoring (premedication with antipyretic and antihistamine may be considered.)
For suspected immune related adverse reactions, ensure adequate evaluation to confirm aetiology or exclude other causes. Based on the severity of the adverse reaction:

- Withhold pembrolizumab and administer corticosteroids. Upon improvement to Grade ≤ 1, corticosteroid taper should be initiated and continued over at least 1 month.
- Consider restarting pembrolizumab within 12 weeks after last dose if the adverse reaction remains at Grade ≤ 1 and corticosteroid dose has been reduced to ≤10 mg prednisone or equivalent per day.
- Pembrolizumab must be permanently discontinued for any Grade 3 immune related adverse reaction that reoccurs a second time, and for any Grade 4 immune related adverse reaction (except for endocrinopathies that are controlled with replacement hormones.)
- Based on limited data from clinical studies in patients whose immune related adverse reactions could not be controlled with corticosteroid use, administration of other systemic immunosuppressants can be considered.

**Immune Related Pneumonitis**
Monitor patients for signs and symptoms of pneumonitis. Confirm suspected pneumonitis with radiographic imaging, and exclude other causes:

- Administer corticosteroids for Grade ≥ 2 events (initial dose of 1-2 mg/kg/day prednisone or equivalent followed by a taper.)
- Withhold pembrolizumab for Grade 2 pneumonitis, and permanently discontinue for Grade 3, Grade 4 or recurrent Grade 2 pneumonitis.

**Immune Related Colitis**
Monitor patients for signs and symptoms of colitis, and exclude other causes:

- Administer corticosteroids for Grade ≥ 2 events (initial dose of 1-2 mg/kg/day prednisone or equivalent followed by a taper.)
- Withhold pembrolizumab for Grade 2 or Grade 3 colitis, and permanently discontinue for Grade 4 colitis.

**Immune Related Endocrinopathies**
Severe endocrinopathies, including hypophysitis, type 1 diabetes mellitus, diabetic ketoacidosis and thyroid disorders have been observed with pembrolizumab treatment. Long term hormone replacement therapy may be necessary in cases of immune related endocrinopathies.

Monitor patients for hyperglycaemia or other signs and symptoms of diabetes (including diabetic ketoacidosis):

- Administer insulin for type 1 diabetes.
- Withhold pembrolizumab in cases of Grade 3 hyperglycaemia until metabolic control is achieved.

Monitor patients for signs and symptoms of hypophysitis (including hypopituitarism and secondary adrenal insufficiency) and exclude other causes:
- Administer corticosteroids to treat secondary adrenal insufficiency and other hormone replacement as clinically indicated.
- Withhold pembrolizumab for symptomatic hypophysitis until event is controlled with hormone replacement.
- Continuation of pembrolizumab may be considered, after corticosteroid taper, if needed.
- Monitor pituitary function and hormone levels to ensure appropriate hormone replacement.

Thyroid disorders, including hypothyroidism, hyperthyroidism and thyroiditis, have been reported in patients receiving pembrolizumab and can occur at any time during treatment. Patients must therefore be monitored for changes in thyroid function (at the start of treatment, periodically during treatment and as indicated based on clinical evaluation) and clinical signs and symptoms of thyroid disorders:
- Hypothyroidism may be managed with replacement therapy without treatment interruption and without corticosteroids.
- Hyperthyroidism may also be managed symptomatically.
- Withhold pembrolizumab for Grade ≥ 3 until recovery to Grade ≤ 1 hyperthyroidism.
- For patients with Grade 3 or Grade 4 hyperthyroidism that improved to Grade 2 or lower, continuation of pembrolizumab may be considered, after corticosteroid taper, if needed.
- Thyroid function and hormone levels should be monitored to ensure appropriate hormone replacement.

**Renal Impairment**
No adjustment of the starting dose is needed in patients with mild or moderate renal impairment, but not recommended in patients with severe renal impairment or end stage renal disease.

**Hepatic Impairment**
No adjustment of the starting dose is needed in patients with mild hepatic impairment, but not recommended in patients with moderate or severe hepatic impairment.

**TREATMENT LOCATION**
Cancer Centre and Cancer Units*

Cancer units must have arrangements for monitoring and management of immune related toxicities and access to advices from oncologist experienced in use of immunotherapies.
REFERENCES

- Summary of Product Characteristics: Pembrolizumab (KEYTRUDA®)


- Early Access to Medicines Scheme- Treatment protocol- Information for healthcare professionals.

### Document Control

<table>
<thead>
<tr>
<th>Document Title</th>
<th>Pembrolizumab for Melanoma S16 003</th>
</tr>
</thead>
<tbody>
<tr>
<td>Document No</td>
<td>CHEMO S16 003</td>
</tr>
<tr>
<td>Current Version</td>
<td>1.0</td>
</tr>
<tr>
<td>Authors</td>
<td>Emma Franklin, pre-registration Pharmacist, Northumbria</td>
</tr>
<tr>
<td>Approved by</td>
<td>Steve Williamson Consultant Pharmacist, NHS England</td>
</tr>
<tr>
<td>Approval Date</td>
<td>04.11.16</td>
</tr>
<tr>
<td>Review Date</td>
<td>04.11.18</td>
</tr>
<tr>
<td>Summary of Changes</td>
<td></td>
</tr>
</tbody>
</table>